The US Food and Drug Administration has approved suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

The new FDA-approved pain drug is suzetrigine, with the brand name Journavx. Suzetrigine is designed to alleviate moderate to ...

The FDA’s approval is based on clinical trials in people recovering from two types of surgeries — tummy tucks and surgical bunion removals — that showed suzetrigine meaningfully reduced pain ...

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

The FDA has approved the first new type of pain medication in more than two decades — and it’s not an opioid. The drug is Suzetrigine under the brand name Journavx. It is now FDA-approved to treat ...

whose NaV1.8 inhibitor suzetrigine (formerly VX-548) has already been filed for approval in the US for two moderate-to-severe acute pain indications, with an FDA decision due by 30th January after ...